Amylyx Pharmaceuticals (AMLX) Free Cash Flow (2021 - 2026)

Amylyx Pharmaceuticals' Free Cash Flow history runs 6 years deep, the most recent figure standing at -$36.9 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 7.41% year-over-year to -$36.9 million in Q1 2026; TTM through Mar 2026 was -$120.5 million, a 41.8% increase from a year earlier, with the FY2025 full-year figure at -$123.5 million, up 26.41% from the prior year.
• Free Cash Flow fell to -$36.9 million in Q1 2026 per AMLX's latest filing, from -$28.0 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $13.2 million in Q4 2023 and bottomed at -$66.7 million in Q2 2024.
• The 5-year median for Free Cash Flow is -$36.9 million (2026), against an average of -$29.4 million.
• Across the five-year window, Free Cash Flow surged 126.22% in 2023 and slumped 7064.57% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$50.3 million in 2022, then jumped by 126.22% to $13.2 million in 2023, then tumbled by 547.35% to -$59.0 million in 2024, then jumped by 52.58% to -$28.0 million in 2025, then sank by 31.77% to -$36.9 million in 2026.
• Per Business Quant, the three latest AMLX Free Cash Flow figures stand at -$36.9 million (Q1 2026), -$28.0 million (Q4 2025), and -$30.4 million (Q3 2025).